Table E1.
Clinical characteristics of NANA healthy control adults and adults with mild-to-moderate AA used for bronchial biopsies
| Clinical characteristics | NANA subjects | Patients with AA | P value |
|---|---|---|---|
| No. | 14 | 17 | NA |
| Sex | 43% M/57% F | 76% M/24% F | |
| Age (y) | 40 (24-55) | 34 (21-51) | .6196 |
| ACQ score | 0 | 0.6 (0-3) | NA |
| ICS (% of patients) | 0 | 71 | NA |
| ICS and LABA (% of patients) | 0 | 53 | NA |
| Exacerbations/year | 0 | 1 (1-4) | NA |
| Oral steroid courses/year (n) | 0 | 0 (0-1) | NA |
| PEF (% predicted) | 99 (85-123) | 91 (66-123) | .1901 |
| FEV1 (% predicted) | 95 (80-107) | 89 (56-133) | .4625 |
| FEV1/FVC ratio (%) | 88 (78-95) | 76 (67-91) | .0002 |
| PC20 histamine (mg/mL) | ≥16 (NA) | 1 (0-4) | .0002 |
| Total serum IgE (U/mL) | 9.5 (2-64) | 127.0 (23-970) | <.0001 |
| SPT (no. of positive responses) | 0 (0-0) | 4 (1-6) | NA |
Values are presented as medians (ranges), except for sex, ICS, and ICS plus LABA. Statistical differences were calculated by using the Mann-Whitney U test.
ACQ, Asthma control questionnaire; F, female; FVC, forced vital capacity; ICS, inhaled corticosteroids; LABA, long-acting β2-agonists; M, male; NA, not applicable; PEF, peak expiratory flow; SPT, skin prick test.